Shares of Athira Pharma Inc. (ATHA) are down nearly 62% from their all-time high of $34.25, recorded last January, and trade around $13. The company has an important catalyst to watch this year.
Athira is a late clinical-stage biopharmaceutical developing small molecules to restore neuronal health and stop neurodegeneration. The lead therapeutic candidate is ATH-1017, being developed for Alzheimer's and Parkinson's disease dementia.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.